Today: 11 June 2026
Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally
19 May 2026
2 mins read

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

New York, May 18, 2026, 20:03 (EDT)

Major U.S. index ETFs were flat to lower late Monday, with the Nasdaq and S&P 500 both edging down in the session as investors trimmed tech holdings and tracked oil and yields. The SPDR S&P 500 ETF Trust slipped 0.1% to $738.65. The Invesco QQQ Trust, which mirrors the Nasdaq 100, dropped 0.4% to $705.88. The DIA ETF, tracking the Dow, gained 0.3% at $497.01.

The move comes just days after the S&P 500 and Nasdaq hit record highs. On Monday, the Dow gained 159.95 points, or 0.3%, to close at 49,686.12. The S&P 500 edged down 5.45 points, or 0.1%, to 7,403.05. The Nasdaq lost 134.41 points, or 0.5%, finishing at 26,090.73.

Stocks didn’t see broad selling, but tech was weak. Reuters said traders pulled money out of tech names while Treasury yields and oil held inflation fears in place. The Philadelphia Semiconductor Index fell 3.3%. Energy shares outperformed, with the S&P 500 energy sector gaining 1.8%. “Oil prices were moving markets on a day-to-day basis,” said Burns McKinney, portfolio manager at NFJ Investment Group. Reuters

The 10-year Treasury yield rose earlier to a high not seen since February 2025, according to Reuters. Rising yields put pressure on stocks, since they make future earnings less attractive, which often hits high-priced tech stocks most. Nathan Peterson, director of derivatives research and strategy at the Schwab Center for Financial Research, said higher yields are “not necessarily a bull market killer,” but noted that how fast yields move is important. Schwab Brokerage

Nvidia stayed the main name for that trade. Shares dropped 1.4% to $222.32 late. Advanced Micro Devices dropped 0.7% to $420.99. Nvidia’s results are expected Wednesday. Its weight gives the stock outsized pull on both the Nasdaq and the S&P 500.

Oil held on to a central role in markets. U.S. crude finished up more than 3% but later trimmed those gains as President Donald Trump said he paused a planned Iran strike to open the door to talks, according to Reuters. Bloomberg listed crude at $107.37, while the U.S. 10-year yield was at 4.59%.

NextEra Energy and Dominion Energy are merging in an all-stock deal. Dominion investors will get 0.8138 NextEra shares for every Dominion share held. NextEra CEO John Ketchum tied the move to surging demand for power, saying, “Electricity demand is rising faster than it has in decades,” with data centers and larger grids fueling growth. Utilities took notice of the news. NextEra Energy Newsroom

Dominion jumped 9.4% to $67.56 after the deal news, but buyers didn’t get the same reaction. NextEra dropped 4.6% to $89.04. Reuters put the value of the deal at $66.8 billion, saying it would make one of the biggest electric utilities worldwide, but it’s still up to regulators.

Regeneron was the big loser. Shares dropped 9.9% to $629.68 after its melanoma therapy failed in a late-stage trial. BMO Capital Markets’ Evan Seigerman said “back-to-back key pipeline misses” are putting pressure on Regeneron’s drug development. Reuters pointed out the trial stacked Regeneron’s combo therapy against Merck’s Keytruda. There’s another trial in progress comparing it to Bristol Myers Squibb’s Opdualag. Reuters

Retail earnings could give the next signal on the consumer. Home Depot traded up 0.9% to $299.81 with results set for Tuesday. Walmart added 1.4% to $133.34 before it reports later this week. Barron’s described expectations for Home Depot as muted, with higher rates and weak housing still weighing on demand for home-improvement projects.

But things can change late in the day. Oil moving higher or more gains in Treasury yields would put new pressure on the soft landing view. Higher oil means more inflation worries. Higher rates could weigh on prices. If Nvidia misses, the AI names might get hit, and that trade could unwind fast. Small caps and consumer stocks might not offer much shelter.

Right now, markets look cautious but not panicked. The Dow stayed steady, energy picked up buyers, and big tech paused after a run. So Tuesday comes down to the Gulf headlines again and how bonds respond.

Stock Market Today

  • Microsoft (MSFT) Stock Seen 14.7% Undervalued Amid Recent Price Dip
    June 11, 2026, 11:06 AM EDT. Microsoft's (MSFT) share price has declined year-to-date to $397.36, prompting investor reassessment of valuation. Recent analysis suggests a fair value of $466 per share, implying the stock is 14.7% undervalued based on strong earnings, margins, and growth potential in AI and cloud sectors. Bull and bear cases range from $804 to $229. Risks include regulatory pressures on cloud licensing, which could impact future returns. Despite short-term weakness, Microsoft remains supported by its long-term shareholder returns. Investors are advised to evaluate opportunities and risks amid mixed market sentiment and explore other AI infrastructure stocks for diversification.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
ServiceNow Jumps After Wall Street Shifts AI View
Previous Story

ServiceNow Jumps After Wall Street Shifts AI View

Ameren Holders Approve CEO Compensation, $14 Million Package Not Unanimous
Next Story

Ameren Holders Approve CEO Compensation, $14 Million Package Not Unanimous

Go toTop